Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269763 | 0.68 | MAPT (0.68) | ALOX15TDP1MAPTGAAPOLB | |
| SCHEMBL1232231 | 0.67 | — | — | |
| SCHEMBL4440495 | 0.66 | — | — | |
| SCHEMBL9123630 | 0.64 | — | — | |
| SCHEMBL11824577 | 0.64 | — | — | |
| SCHEMBL30620456 | 0.59 | HPGD (0.38) | ALDH1A1EGFRCA2LMNAFYN | |
| SCHEMBL25879812 | 0.58 | PIM1 (0.39) | ALDH1A1EGFRCA2LMNAFYN | |
| SCHEMBL1042592 | 0.58 | MAPT (0.63) | ALDH1A1CA2LMNAHPGDALOX15 | |
| Catechol SCHEMBL27748890 | 0.57 | — | — | |
| SCHEMBL21048130 | 0.55 | MAPT (0.53) | ALDH1A1CA2LMNAHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884802-B2 | 6-heteroarylphenanthridines | ALTANA PHARMA AG (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040038979-A1 | Treating airway disorders such as asthma. | ALTANA PHARMA AG (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1303506-A1 | 6-HETEROARYLPHENANTHRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006270-A1 | NOVEL 6-HETEROARYLPHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038979-A1 | Treating airway disorders such as asthma. | PTGER4, PDE4B, PDE4A | ALDH1A1 779/4885EGFR 4309/4885CA2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.